申请人:Pfizer Inc.
公开号:US04900839A1
公开(公告)日:1990-02-13
A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared, including the 3,4-dihydro derivatives thereof, wherein the heterocyclic ring moiety is a pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the 5-, 6-, 7- or 8-positions of the quinolone ring. These particular compounds are useful in therapy as highly potent inotropic agents and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, 6-(2,4-dimethyl-5-nitroimidazol-1-yl)-8-methyl-2-(1H)-quinolone, 8-methyl-6-(tetrazol-1-yl)-2-(1H)-quinolone, 8-methyl-6-(1,2,4-triazol-4-yl)-2-(1H)-quinolone, and 6-(4-cyano-2-methylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, respectively. Methods for preparing these compounds from known starting materials are provided.
已经制备了一系列新颖的杂环取代的2-(1H)-
喹诺酮化合物,包括其3,4-二氢衍
生物,其中杂环环基是通过该基团的氮原子连接到
喹诺酮环的5、6、7或8位的
吡咯基、
咪唑基、
吡唑基、三唑基或
四唑基。这些特定的化合物在治疗中具有高效的正性肌力作用,因此在治疗各种心脏疾病方面具有价值。优选的化合物成员包括6-(
2,4-二甲基咪唑-1-基)-8-甲基-2-(1H)-
喹诺酮、6-(2,4-二甲基-5-硝基
咪唑-1-基)-8-甲基-2-(1H)-
喹诺酮、
8-甲基-6-(四唑-1-基)-2-(1H)-喹诺酮、
8-甲基-6-(1,2,4-三唑-4-基)-2-(1H)-喹诺酮和6-(4-
氰基-
2-甲基咪唑-1-基)-8-甲基-2-(1H)-
喹诺酮。提供了从已知起始材料制备这些化合物的方法。